B9A Stock Chart & Stats
€28.52
-€0.37(-2.00%)
At close: 4:00 PM EST
€28.52
-€0.37(-2.00%)
Day’s Range― - ―
52-Week Range€16.91 - €34.96
Previous CloseN/A
Volume0.00
Average Volume (3M)292.00
Market Cap
€2.42B
Enterprise Value€25.01B
Total Cash (Recent Filing)€2.03B
Total Debt (Recent Filing)€40.74M
Price to Earnings (P/E)125.1
Beta0.58
Next Earnings
Aug 26, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.41
Shares Outstanding74,324,486
10 Day Avg. Volume102
30 Day Avg. Volume292
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)13.99
Price to Sales (P/S)13.76
P/FCF Ratio19.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.22
Revenue Forecast (FY)€105.88M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthBioArctic’s very strong balance sheet, with low debt versus equity and materially growing equity, provides durable financial flexibility. This supports funding of R&D, absorbing clinical timing shocks, and negotiating partnerships without pressure to dilute or sell assets, strengthening long-term optionality.
Cash Generation In 2025/TTMOperating cash flow well above net income in recent periods indicates high cash conversion when milestones or royalties are realized. That cash-generative capacity can fund development and partner co‑funding, supporting sustainable operations and reducing external financing needs over the medium term.
Partnership-Driven Business ModelBioArctic’s licensing-and-royalty model leverages partners for late‑stage development and commercialization, lowering capital intensity and operational burden. Successful collaborations (e.g., Eisai) can create scalable royalty streams and milestone uplifts, aligning upside with partner execution while preserving cash.
Bears Say
Revenue And Earnings VolatilityHistoric swings from losses to very strong profits and a steep TTM revenue decline make forecasting difficult. Reliance on episodic milestones and irregular royalty timing amplifies volatility, increasing risk to consistent earnings, budgeting for R&D, and sustaining investor confidence across 2–6 month horizons.
Partner-Dependent Revenue RiskThe company’s monetization depends on partner decisions, regulatory success, and market adoption outside its control. This limits BioArctic’s ability to smooth revenue, makes cashflows timing-uncertain, and concentrates execution risk on partners’ development, approval, and commercialization capabilities.
Free Cash Flow VolatilitySignificant swings in free cash flow, including negative periods, indicate sensitivity to milestone timing, working capital, and reinvestment. This volatility can pressure near-term liquidity, force opportunistic financing, or delay programs when cash inflows from partners or royalties underperform expectations.
BioArctic AB Class B News
B9A FAQ
What was BioArctic AB Class B’s price range in the past 12 months?
BioArctic AB Class B lowest stock price was €16.91 and its highest was €34.96 in the past 12 months.
What is BioArctic AB Class B’s market cap?
BioArctic AB Class B’s market cap is €2.42B.
When is BioArctic AB Class B’s upcoming earnings report date?
BioArctic AB Class B’s upcoming earnings report date is Aug 26, 2026 which is in 40 days.
How were BioArctic AB Class B’s earnings last quarter?
BioArctic AB Class B released its earnings results on May 20, 2026. The company reported €0.22 earnings per share for the quarter, beating the consensus estimate of -€0.028 by €0.248.
Is BioArctic AB Class B overvalued?
According to Wall Street analysts BioArctic AB Class B’s price is currently Overvalued.
Does BioArctic AB Class B pay dividends?
BioArctic AB Class B does not currently pay dividends.
What is BioArctic AB Class B’s EPS estimate?
BioArctic AB Class B’s EPS estimate is -0.03.
How many shares outstanding does BioArctic AB Class B have?
BioArctic AB Class B has 74,324,486 shares outstanding.
What happened to BioArctic AB Class B’s price movement after its last earnings report?
BioArctic AB Class B reported an EPS of €0.22 in its last earnings report, beating expectations of -€0.028. Following the earnings report the stock price went up 1.716%.
Which hedge fund is a major shareholder of BioArctic AB Class B?
Currently, no hedge funds are holding shares in DE:B9A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioArctic AB Class B
BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of innovative biological drugs, such as antibodies that address high unmet medical needs. The company’s therapeutic areas encompass neurodegenerative disorders, such as Alzheimer’s disease, Parkinson’s disease, and other CNS diseases. In addition, it owns a technology platform, which develops a range of therapeutic monoclonal antibodies. Additionally, the company is developing lecanemab, which is in phase 3 clinical trials; Lecanemab that is in back-up phase 3 clinical trials; Exidavnemab, which is in phase 2 clinical trials; Lecanemab, BAN2803, and BAN2802 that are in preclinical trials; and BAN1503, PD-BT2238, ND-BT3814, and GD-BT6822, which are in discovery stage. It has research collaboration agreements with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.
Technical Analysis
Hansa Biopharma AB
―
BioInvent International AB
―
Vicore Pharma Holding AB
―
Xspray Pharma AB
―
Cantargia AB
―